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Familial Mediterranean fever is known as a most frequent hereditary 
autoin-Xammatory  among  the  autoinflammatory  syndromes  characterised  by 
fever,  arthritis  and  serosal  inflammation.  Clinically,  the  foremost  severe 
symptom of the disease is amyloidosis, which may cause to renal failure. MEFV 
renal failure consists of ten exons and conservative mutations clustered in exon 
ten (M694V, V726A, M680I, M694I) and exon two (E148Q) are considered 
more common mutations within this coding region and that they are detected 
with a distinct frequency changes in line with ethnicity. The aim of this study 
was to research the spectrum of mutations in Azeri Turkish population. 
We evaluated the molecular test results of 82 patients and their parents from 
eighty  families  identified  as  having  FMF  clinical  symptoms  referred  to 
Molecular Genetics Laboratory of the Department of Medical Genetics. Patients 
were  referred  by  their  physicians  for  MEFV  mutation  detection.  The  most 
frequent  mutations  were  M694V  respectively  followed  by  M680I  (G/C), 
V726A,  M694I  and  E148Q  mutations.  A  phenotypic  variability  was  also 
ascertained between patients with different mutations and it must be considered 
within the daily management of FMF patients.  
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INTRODUCTION 
Familial  Mediterranean  fever  (FMF,  MIM249100)  is  one  among  the  autosomal 
recessive disorders that characterised by continual attacks of fever and inflammation within the 
peritoneum,  synovium  and  pleura,  accompanied  by  pain.  The  clinical  symptoms  can  be 
developed variously in different patients, sometimes even within the same family by recurring 
serositis leading to pain in the abdomen, chest, joints and muscles. Amyloidosis just like that 
seen in other chronic inflammatory diseases like rheumatoid arthritis, is that the most severe 
complication of FMF and leads to renal failure. Also, concerning these destructive arthritis and 
potentially  life  threatening  secondary  amyloidosis  are  assumed  because  the  major  long-term 
complications associated with the disease (PRAS et al. 1998; CAZENEUVE et al. 1999; LIVNEH et 
al. 1999; SHOHAT et al. 1999; TAMIR et al. 1999; BRIK et al. 2001; NOTARNICOLA et al. 2002; 
GERSHONI-BARUCH et al. 2003).  
FMF is reported more frequently in the people with the origin from the Mediterranean 
region (non-Ashkenazi Jews, Armenians, Sephardic Jews, Turks, Greeks, Druze and Arabs), 
which are considered as classically at risk ethnic groups. This phenotype is less common in other 
populations  of  Mediterranean  ancestry,  with  the  carrier  individuals  and  the  severity  of  the 
clinical symptoms of the disease varying considerably both among and within different races. 
The discovery of FMF causing gene (GenBank af018080) has prepared possibilities to study the 
distribution of various mutations in geographically and ethnically different groups (HOLMES et al. 
1998; PRAS et al. 1998; AKSENTIJEVICH et al. 1999; CAZENEUVE et al. 1999; TAMIR et al. 1999; 
BOOTH et al. 2001; BRIK et al. 2001; MANSOUR et al. 2001; YILMAZ et al. 2001; NOTARNICOLA et 
al. 2002; AL-ALAMI et al. 2003; GERSHONI-BARUCH et al. 2003; ALDEA 2004; ATAGUNDUZ et al. 
2004; AYESH et al. 2005; SARKISIAN et al. 2005; BELMAHI et al. 2006; MATTIT et al. 2006). The 
candidate  gene is located  on chromosome  16p13.3 and it has been recognized by  positional 
cloning in the summer of 1997. The locus composes of 10 exons and encodes 781 amino acid 
protein that named pyrin/marenostrin that is predominantly expressed in polymorph nuclear cells 
as well as in cytokine activated monocytes. It seems that assist normally in keeping inflammation 
under control by inhibiting interleukin-1 (IL-1) processing and permitting macrophageapoptosis, 
without this control, an in appropriate full-blown inflammatory reaction occurs. To date, 218 
MEFV gene alterations (polymorphisms/mutations) have been reported as responsible for the 
phenotypic  variance seen in  the disease that most  of them are substitutions; 78  of them are 
missense,  one  nonsense,  39  silent  mutations,  17  are  located  in  introns,  two  in  UTS,  one  is 
duplication, two are insertions and two are deletions (Holmes et al. 1998; Hull et al. 2003).  
Between the investigated mutation frequencies in classically affected populations, five 
responsible  for  more  than  70%  of  affected  patient  (V726A,  M694V,  M694I,  M680I  and 
E148Q7) (SHINAWI et al. 2000; GERSHONI-BARUCH et al. 2001). The tenth exon has the first four 
mutations reported in FMF and has the forty-eight of the MEFV mutations. Numerous reports 
have revealed that FMF may be provoked in carriers of a single mutation by factors unrelated to 
the other MEFV allele (LIVNEH et al. 2001). These secondary factors such as modifier genes, sex 
and ethnicity can alter the pattern and appearances of the disorder beside the detected mutations 
that can cause the different rate of clinical manifestation (DEWALLE et al. 1998; PRAS et al. 1998; 
AKSENTIJEVICH et al. 1999; TAMIR et al. 1999; YALÇINKAYA et al. 2000; LIVNEH et al. 2001; 
TOUITOU 2001; TOUITOU et al. 2001; NOTARNICOLA et al. 2002; CAZENEUVE et al. 2003; PADEH 
et al. 2003).  
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MATERIALS AND METHODS 
Subjects 
This study was conducted in the Department of Medical Genetics, Faculty of Medicine, 
University of Medical Sciences, and Tabriz, Iran. Our patients were screened by their physicians 
for MEFV mutation detection. 
 
Criteria for Diagnosis of FMF Patients 
Our  patients  were  selected  from  north-west  of  Iran  with  Azeri  Turkish  origin  and 
clinical diagnosis  of  FMF  has until  recently  been  based  upon  the published  clinical  criteria 
(Livneh et al. 1997) and all FMF subjects were diagnosed by expert clinicians regarding to: 1- 
probands and/or  sibs with two  FMF causing mutations in the  MEFV  gene (homozygotes  or 
compound heterozygotes); and 2- probands found to carry only one known mutation but who 
demonstrated characteristic FMF symptoms that  met  the diagnostic criteria and who  had no 
family history of FMF that could suggest a carrier state by descent. The diagnosis of phenotype 
in siblings when the proband was found to have two FMF mutations has been evaluated for 
presence of these same mutations in the sibling and when the proband had only one known 
mutation,  it  was  based  on  the  detection  of  the  sharing  of  two  alleles  with  the  proband. 
Asymptomatic  individuals  with  carrying  mutations  in  both  alleles  were  considered  affected. 
Written consent was obtained from the parents of the children. 
 
Genomic DNA extraction 
Genomic DNA was isolated from EDTA anticoagulated blood using the total DNA 
extraction kit (Qiagen, Hilden, Germany), according to manufacturer's instructions. 
Mutation Analysis 
To screen for these mutations, we have selected direct PCR cleavage methods based on 
the in compliance of constitutive restriction sites or the implementation of a restriction site in 
either the wild type or the mutant allele. Identification of mutations M694V and V726A were 
executed by PCR with primers (FMF-A: 5’-GAATGGCTACTGGGTGGAGAT-3’) and (FMF-
B: 5’-GGCTGTCACATTGTAAAAGGAG-3’). Amplification conditions were 94
°C for 4 min 
followed by 30 cycles of: 40s at94
°C, 30s at 56.2
°C, and 1 min at 72°Cand 10 min incubation at 
72
°C. Normal allele does not have any Hph-I restriction site for M694V proximal to the mutation, 
on the contrary, creates a site in the PCR product of the mutant allele. Digestion with Hph-I the 
mutant allele yields one 118-bp and one 36-bp fragments and the normal allele gives a 154-bp 
uncut fragment. Mutant allele have an Alu-I restriction site in the PCR product for theV726A. 
Subsequent  digestion  by  Alu-I,  the  normal  allele  yields  a  154-bp  uncut  fragment  whilst  the 
mutant allele gives one 122-bp and one 32-bp fragment. Mutation detection for M694I was done 
by substituting a base in the sequence of primer FMF-C turn this way locates adjacent to the 
mutation  locus  and  a  BspH-I  restriction  site  was  produced  in  the  normal  allele.  Designated 
conditions  above  were  used  to  fragment  amplification  with  FMF-C  (5’-
GCTACTGGGTGGTGATAATCAT-3’) and FMF-B primers. After cleavage with BspH-I, the 
mutant  allele  gives  a  149-bp  uninterrupted  fragment  whilst  yields  a  130-bp  and  a  19-bp 
fragments  for  the  normal  allele.  Mutation  M680I  was  investigated  by  primers  FMF-D  (5’-
TATCATTGTTCTGGGCTC-3’)  and  FMF-E  (5’-CTGGTACTCATTTTCCTTC-3’).  The 
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the mutant allele yields a 184-bp uncut fragment. The amplification conditions for these primers 
were 94
°C for 4 min that followed by 30 cycles of: 40s at 94
°C, 45s at 55
°C, and 1 min at 72
°C and 
10  min  final  incubation  at  72
°C.  The PCR products  were  separated  on  8%  non-denaturating 
polyacrylamide gel. The comprising region of E148Q mutation was analyzed using primers F: 
5’-GCCTGAAGACTCCAGACCACCCCG-3’and R: 5’-GGCCCTCCGAGGCCTTCTCTCTG-
3’ with an annealing temperature of 69°CC. 157bp PCR product was restricted with BstN1, 
which recognizes the mutation. 
We analyzed exon 2, 3, 4 and exon 10 of the MEFVgene for all patients by bidirectional 
sequencing method that did not appeared above mentioned mutations. We tested 5´ end of exon 
2  by  PCR  amplification  using  the  forward  primer  F:  5´-
ATCATTTTGCATCTGGTTGTCCTTCC-3  and  the  reverse  primer  R:5-
TCCCCTGTAGAAATGGTGACCTCAAG-3.  The  PCR  reaction  was  performed  under  the 
following conditions: 95
°C for 2 minutes followed by 30 cycles of 95
°C for 30s, 59.6
°C for 30s and 
72
°C for 30s, and final extension at 72
°C for 10 minutes. Also 3´ end of exon 2 was amplified by 
forward primer F: 5´-GGCCGGGAGGGGGCTGTCGAGGAAGC-3 and the reverse primer R: 
5-TCGTGCCCGGCCAGCCATTCTTTCTC-3.  Exon  10  primers  were  forward  primer  F:  5´-
CCAGAAGAACTACCCTGTCCC-3  and  the  reverse  primer  R:  5-
CAGAGCAGCTGGCGAATGTAT-3.  PCR  products  were  purified  with  the  High  Pure  PCR 
Product  Purification  kit  (Roche,  Germany)  and  sequenced  directly;  using  specific  primers. 
Twenty one individuals without any symptoms of FMF were also investigated in the study as 
controls.  Also,  exons  3  and  4  were  amplified  by  forward  primer  F:  5´- 
CACAGCAGAATCTCGGGG-3 and the reverse primer R: 5- GCACATCTCAGGCAAGGG-3. 
RESULTS  
The MEFV gene has recently been identified and major missense mutations causing 
FMF  were  described  (FRENCH  FMF  CONSORTIUM,  1997;  INTERNATIONAL  FMF  CONSORTIUM, 
1997).  Using  this  panel  of  direct  PCR  based  tests  we  characterized  mutation  bearing 
chromosomes from our patient group comprised 82 unrelated Azeri Turkish FMF patients, of 
whom  27  were  homozygous  M694V  and  24  were  heterozygous  for  one  MEFV  mutation 
(M694V=22;  M694I  =4;  V726A=6;  M680I=4;  E148Q=2).  Sixteen  different  mutations  were 
identified in these cases; five of them were frequently observed (Table1), while others were only 
detected at the heterozygous state (Table1) in affected individuals. 
Table 1: Frequencies of the studied founder mutations in analyzed alleles in the target population. 
Mutation type  Number of alleles 
Genotype Status 
Total Allele frequency (%) 
Homozygous  Heterozygous 
M694V  76  27  22  46.34 
M694I  14  5  4  8.54 
V726A  18  6  6  10.97 
M680I  22  9  4  13.41 
E148Q  8  3  2  4.89 
Other*  12  1  -  7.31 
Unknown  14  -  -  8.54 
Total  164      100 
* R202Q, R653H, R408Q, S675N, G678E, M680L, I720M, I692del, M694L, T681I and A744SM mutations.  J.GHARESOURAN  et al: FAMILIAR MEDITERRANEAN FEVER MUTATION                                           615 
On  the  other  hand,  E148Q  and  R202Q  mutations  in  exon  2  were  detected  in  each 
homozygous and heterozygous states and R408Q in exon 3 were detected only in heterozygous 
state. The observed MEFV genotypes are summarized in Table 1. Since the majority of FMF 
patients can be carrier of one or two of five mutations, obtained clinical information from them 
showed phenotypic variability in compare with the genotypic data (Table2). 
Table 2. Analysis of presenting clinical manifestations of FMF cases 
Clinical 
manifestations 
S c o r e 
1  2  3 
Family history  Negative (67.8%)  Positive (32.2%)  - 
Consanguinity  Negative (42.7%)  Positive (57.3%)  >5 days 
Duration of each 
attack 
3> days (27.6%)  3-5 days (69.1%)  >30 year (3.3%) 
Frequency of 
attacks 
10> year (12.2%)  10-30 year (71.4%)  (16.4%) 
Fever  Negative (10.6%)  Up to 39o 
C (12.3%)   <39
o 
C  (77.1%) 
Abdominal pain*  Negative (9.3%)  Moderate (19.1%)  Severe (71.6%) 
Joint affection  Negative (52.7%)  Arthralgia (44.8%)  Arthritis (2.5%) 
Chest pain*  Negative (41.2%)  Moderate (56.9%)  Severe (1.9%) 
Myalgia*  Negative (54.1%)  Moderate (45.3%)  Severe (1.6%) 
Operations  Negative (82.5%)  Positive (17.5%)  - 
 
DISCUSSION 
Polymorphism in the exon 2 region of the DRB1 gene in Iranian Makuie sheep breed 
(fat-tailed sheep breed) was studied by PCR-RFLP. Compared to cattle and other animals, Ovar-
DRB1 locus is poorly studied in Iranian sheep breeds. Different methods have been used to study 
genetic variation in the Ovar-DRB1 gene in various sheep breeds. Among different methods, 
PCR-RFLP analysis has been found a valuable technique in identifying genetic variation of the 
DRB1 gene in farm animals (KONNAI et al., 2003a, b; GRUSZYNSKA et al., 2005).  
Ten alleles and eighteen genotypes were identified in the exon 2 region of the MHC-
DRB1 gene in Makuie sheep breed population. The most frequent allele and genotype were A 
allele and AA genotype in the frequencies of 0.4756 and 0.317, respectively. Our results partly 
were in agreement with the results of KONNAI et al. (2003b) and GRUSZCZYNSKA et al. (2005). 
KONNAI et al. (2003a) reported alleles Q and P in Polish Heath and Polish Lowland sheep breeds 
with 6 and 13 different patterns respectively. GRUSZCZYNSKA et al. (2005) reported alleles B, E, 
D and F in Suffolk sheep breed. Other alleles (A, I, M, O and V) were not reported in sheep 
breeds until now. CHARON et al. (2000) have shown positive association between MHC-DRB1 
alleles with reduced faecal egg counts in parasitic infestations. Ovine MHC class II DRB1 alleles 
reported to be associated with susceptibility to development of bovine leukemia virus-induced 
ovine lymphoma (NAGAOKA et al., 1999). In recent researches we couldn’t find any creature 
without MHC molecules. This truth can indicate that creatures without MHC couldn’t survive 
longtime after their birth because any slight defect or mutation in MHC molecules would cause 
intense immunological disorder (DUKKIPATI et al., 2006b). 616                                                                                                             GENETIKA, Vol. 46, No.2,611-620, 2014 
Shannon’s information index revealed high genetic diversity within studied population. 
The chi-square test showed significant (P ≥ 0.05) deviation from Hardy-Weinberg equilibrium at 
the  MHC-DRB1  gene  in  the  studied  population.  This  was  the  first  report  on  studying  the 
polymorphism in the MHC-DRB1 locus in Makuie sheep breed. The previous breeding programs 
in the most research centers of Iran were based on only phenotypic characters. This study may be 
considered as an introductory to understanding the genetic variability on native sheep breeds in 
the  Azerbaijan  regions  by  using  molecular  techniques  that  do  not  affect  by  environmental 
effects.   
 
Table 3: A comparison of results obtained from various studies in population with different origins 
Origin  Main gene mutation respectively by percent 
Algeria  M694I, M694V, E148Q, A744S, M680I 
Azeri Turks  M694V, M680I, V726A, M694I, E148Q 
Armenia  M694V, V726A, M680I, E148Q, M694I,  R761H 
Egypt  V726A, M694V, M680I, E148Q, M694I 
France  E148Q, M694V, M694I,  
Greece  M694V, V726A, E148Q, M694I 
Jews  M694V, V726A, M680I, M694I, E148Q 
Jordan  M694V, V726A, M680I, E148Q, M694I 
Italy  M694V, E148Q, M680I,M694I, V726A 
Iraq  M694V, V726A, E148Q 
Kuwait  V726A, M694I, M694V, A744S 
Lebanon  M694V, V726A, M694I, M680I, E148Q 
Morocco  M694V, M694I, A744S, M680L, E148Q 
Palestine  M694V, V726A, M694I, M680I, E148Q 
Syria  M694V, M694I, M680I, V726A, E148Q 
Spain  M694V, E148Q 
Tunisia  M694V, M694I, A744S, E148Q 
Turks  M694V, E148Q, M680I, V726A, P369S 
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Izvod 
Porodična Mediteranska groznica (FMF)  je poznata kao najučestalija nasledna recesivna bolest 
unutar  autoinflamatornog  sindroma  čije  karakteristike  su  groznica,  arthritis  i  ozbiljne  upale.   
Klinički,  simptom  najistaknutiji  symptom  ove  bolesti  je  amiloidoza,  koja  može  da  izazove  
otkazivanje funkcije bubrega. Gen kandidat koji kontroliše ovu bolest je lociran na hromozomu 
16p13.3  koji  je  identifikovan  pozicionim  kloniranjem  1997.  godine  i  kodira  protein 
pyrin/marenostrin.  Lokus  čine  10  egzona  i  konzervativne  mutacije  grupisane  u  egzonu  10 
((M694V, V726A, M680I, M694I) i egzonu 2 ((E148Q). Cilj ovog rada je bio ispitivanje spektra 
mutacija  u  Azeri  Turskoj  populaciji.  Vršena  je  ocena  rezultata  molekularnog  testa  kod  82 
pacijenta  i  njihovih  roditelja  iz  8  porodica  koje  su  imale  ovu  bolest  (FMF)  sa  kliničkim 
simptomima uutvrđenim u laboratoriji za molekularnu genetika odelenja medicinske genetike.  
Najučestalije utvrđene mutacije su M694V a zatim M680I (G/C), V726A, M694I and E148Q. 
Utvrđena je i fenotipska varijabilnost među pacijentima sa različitim mutacijama.  
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